<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03161106</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Cirrhosis-12</org_study_id>
    <nct_id>NCT03161106</nct_id>
  </id_info>
  <brief_title>To Assess Efficacy of Nutritional Therapy in Secondary Prophylaxis of Hepatic Encephalopathy Versus Lactulose in Patients With Liver Cirrhosis.</brief_title>
  <official_title>To Assess Efficacy of Nutritional Therapy in Secondary Prophylaxis of Hepatic Encephalopathy Versus Lactulose in Patients With Liver Cirrhosis- A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted on patients attending /admitted to Department of Hepatology from
      April 2017 to December 2018 at ILBS, New Delhi .

      Clinical, anthropometric and biochemical assessment will be done by candidate, co-supervisors
      and supervisor. Patients in treatment group will receive nutritional therapy in the form of
      30-kcal/kg/day and 1.5gm/kg/day protein with supplements. Other patients will continue diet
      that they were receiving before along with lactulose. Previous treatment and prophylaxis of
      variceal bleed any (endoscopic variceal ligation or beta blocker) will be continued as
      before. All subjects will be followed up every month for treatment compliance and for
      development of any complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients develop hepatic encephalopathy in both groups</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in health related quality of life over 6 months</measure>
    <time_frame>6 Months</time_frame>
    <description>Improvement will be defined on the basis of HRQOL (Health Related Quality of Life Index).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in anthropometry parameters (mid arm circumference, triceps skin fold thickness, hand grip), skeletal muscle mass, body fat mass, percent body fat,BMI over 6 months</measure>
    <time_frame>6 Months</time_frame>
    <description>Improvement will be measured by dexa scan , C T scan and by measuring mid arm circumference, triceps skin fold thickness, hand grip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time taken for first breakthrough episode of overt hepatic encephalopathy</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first overt hepatic encephalopathy-related hospital admission</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality over 6 months</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum cytokines (IL-1,6,10,18,TNF,Endotoxins,myostatin levels)</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Stool microbiota for 20 patients</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Nutrional Therapy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutritional group- Protein of 1.5 gm/kg thrice daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactulose Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactulose - 20 mL thrice daily (maximum) for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutrition</intervention_name>
    <description>Nutrional group-30 kcal/kg with 1.5 grm protein with protein supplements</description>
    <arm_group_label>Nutrional Therapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>Lactulose plus diet consumed by patient</description>
    <arm_group_label>Lactulose Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>Protein Powder 15 to 20 gm/meal/day</description>
    <arm_group_label>Lactulose Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Liver cirrhosis (Child B or Child C class)

          2. Age between 18-60 years

          3. History of recovery from episodeof overt hepatic encephalopathy (West-Haven grade 1
             and above) in last 12 months.

        Exclusion Criteria:

          1. Evidence of overt hepatic encephalopathy at the time of enrollment

          2. History of taking lactulose, rifaximin, neomycin, metronidazole, L-Ornithine
             L-Aspartate or probiotics in past 7 days

          3. Alcohol intake during past 6 weeks

          4. Receiving secondary prophylaxis for spontaneous bacterial peritonitis

          5. Previous transjugular intrahepatic portosystemic shunts or shunt surgery

          6. Significant comorbid illness such as heart, respiratory or kidney failure, and
             neurological disease such as Alzheimer's disease, Parkinson's disease and non hepatic
             metabolic encephalopathies

          7. Receiving psychoactive drugs, promotility and hypomotility drugs

          8. Hepatocellular carcinoma

          9. Electrolyte abnormality (Serum sodium &lt;125meq/L or serum potassium &lt;2.5meq/L)

         10. Intercurrent infection such as spontaneous bacterial peritonitis

         11. Patients of acute on chronic liver failure (ACLF).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Harsh Tevethia, MD</last_name>
    <phone>01146300000</phone>
    <email>hershey4686@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

